Best-in-class treatments in use today
Leukemia is a group of cancers that affect the blood and bone marrow. There are several types of leukemia, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). For many people, treatment involves a combination of chemotherapy, targeted therapy, and supportive care. Here are some of the most important treatments used today:
For AML, the chemotherapy drug cytarabine is often used to induce remission. This is typically followed by a consolidation phase, where other chemotherapy drugs or targeted therapies are used to kill any remaining cancer cells. Targeted therapies like venetoclax and gilteritinib are also used to treat AML, especially in people with specific genetic mutations.
For ALL, chemotherapy is often used to induce remission, followed by a consolidation phase with other chemotherapy drugs or targeted therapies. Targeted therapies like blinatumomab and inotuzumab ozogamicin are used to treat ALL, especially in people with specific genetic mutations.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a type of stem cell transplant that uses stem cells from a donor. This is often used to treat AML and ALL that has not responded to other treatments.
What researchers are actively studying
Researchers are actively studying several new treatments for leukemia, including:
* New combinations of chemotherapy drugs and targeted therapies
* Immunotherapies, which use the body's immune system to fight cancer
* Gene therapies, which aim to fix or replace the genetic mutations that cause leukemia
* CAR-T cell therapy, which uses genetically modified T cells to attack cancer cells
The recent abstracts suggest that researchers are also studying the use of venetoclax and azacitidine as a bridging therapy to second transplantation for post-transplant extramedullary relapse of AML.
Where the evidence stands
The evidence for new treatments for leukemia is at various stages of development. Some treatments are already approved and widely available, while others are still in the early stages of research.
Approved treatments include chemotherapy drugs like cytarabine and targeted therapies like venetoclax and gilteritinib. These treatments have been shown to be effective in clinical trials and are widely used to treat AML and ALL.
Late-stage trials (Phase 3) are testing new combinations of chemotherapy drugs and targeted therapies, as well as immunotherapies and gene therapies. These trials are designed to determine whether these new treatments are safe and effective in a larger group of people.
Early-stage trials (Phase 1-2) are testing new treatments that are still in the early stages of development. These trials are designed to determine the safety and effectiveness of these new treatments in a small group of people.
Preclinical research is the earliest stage of research, where new treatments are being developed and tested in the laboratory. This research is still in its early stages, but it holds promise for the development of new and more effective treatments for leukemia.
What this means for people affected
The research landscape for leukemia is complex and constantly evolving. There are many options available for people with leukemia, and researchers are actively studying new treatments to improve outcomes.
While there are many approved treatments available, not everyone will respond to these treatments. Researchers are working to develop new treatments that are more effective and have fewer side effects.
The field is moving quickly, with new treatments being developed and tested all the time. This means that people with leukemia may have access to new and more effective treatments in the future.
However, there are still gaps in our understanding of leukemia and its treatment. More research is needed to develop effective treatments for people with specific genetic mutations or other high-risk features.